Catalyst Pharmaceutical Partners (CPRX) PT Lowered to $4.50 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat
May 13, 2019 6:04 AM EDTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of ($0.01), $0.12 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $12.4 million versus the consensus estimate of $1.6 million.
Total net revenue in the first quarter 2019 was $12.4 million.Selling, general and administrative expenses for the first quarter of 2019 totaled $8.4 million as compared to $2.7 million in the first quarter of 2018. The increase is primarily attributed to commercial launch expenses, as well as the patient services programs to support... More